GlassScriptPhysician profile
Catherine Riley
NPI 1346770369
$10,941.57
in general payments reported to CMS, 2019-2025
45 companies · $2,834 in 2025
The $2,834 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $117 · 2021: $1,436 · 2022: $2,401 · 2023: $2,452 · 2024: $1,701 · 2025: $2,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,968 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,967.63 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,652.21 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,233.84 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,116.50 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $891.88 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $720.89 | 2021-2025 | Freestyle Libre, Jot Dx |
| Pfizer INC. | $683.61 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $654.54 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $620.43 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $475.60 | 2021-2025 | |
| Astellas Pharma US INC | $239.17 | 2020-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.02 | 2021-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $220.56 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Esperion Therapeutics, INC. | $210.41 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $195.81 | 2020-2025 | Belsomra, Segluromet, Steglatro |
| Amgen INC. | $172.60 | 2021-2025 | Evenity, Otezla, Repatha |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.